Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Cash & Current Investments (2016 - 2025)

Medifast's Cash & Current Investments history spans 16 years, with the latest figure at $167.3 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 3.04% year-over-year to $167.3 million; the TTM value through Dec 2025 reached $167.3 million, up 3.04%, while the annual FY2025 figure was $167.3 million, 3.04% up from the prior year.
  • Cash & Current Investments reached $167.3 million in Q4 2025 per MED's latest filing, down from $173.5 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $212.9 million in Q1 2021 to a low of $61.1 million in Q2 2022.
  • Average Cash & Current Investments over 5 years is $146.0 million, with a median of $158.8 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: plummeted 69.07% in 2022, then soared 141.37% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $109.5 million in 2021, then dropped by 19.95% to $87.7 million in 2022, then soared by 71.1% to $150.0 million in 2023, then grew by 8.2% to $162.3 million in 2024, then rose by 3.04% to $167.3 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Cash & Current Investments are $167.3 million (Q4 2025), $173.5 million (Q3 2025), and $162.7 million (Q2 2025).